Drug Profile
Research programme: mirror-image oligonucleotides - TME Pharma/Roche
Latest Information Update: 01 Aug 2022
Price :
$50
*
At a glance
- Originator NOXXON Pharma AG; Roche
- Developer Roche; TME Pharma
- Class Oligonucleotides
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Inflammation in Germany